Subscribe

News
Academy
Multimedia
Conferences
Publications
Partner Perspectives
Resources
Event Calendar
Subscribe

|Articles|January 1, 2004

Pharmaceutical Executive

Pharmaceutical Executive-01-01-2004

Table of Contents

Table of Contents

External Link - article-80918.pdf

Articles in this issue

over 22 years ago

Article

PE's Annual Sales and Marketing Employment Survey: The Big Squeeze

over 22 years ago

Article

Streamlining For Success with Fred Price of BioMarin

over 22 years ago

Article

The Making of a New Disease

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Content

From Diagnosis to Design: How Physician-Scientists Are Building Future-Ready Pharma Organizations

ByEmmanuelle Clerisme-Beaty, M.D.

August 10th 2026

stock.adobe.com acquire

Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion

ByNicholas Jacobus

August 10th 2026

Your Product Is Ready. Your Launch Strategy Isn't

ByKomal Gurnani

August 10th 2026

stock.adobe.com business deal

M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo

ByNicholas Jacobus

August 10th 2026

Matt Farrell

Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance

August 10th 2026

Trending on PharmExec

The Significance of FDA’s First Warning Letter for Inappropriate Use of AI

Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion

Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance

FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma

The Merger Paradox: Why Transformational Mergers Create Extraordinary Value and Frequently Fail